[
    {
        "content": "* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million  up 158 percent",
        "date": "10302017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences reports qtrly loss per share of $0.23 "
    },
    {
        "content": "Oct 30 Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test  Cologuard  more than doubled.",
        "date": "10302017",
        "name": "Exact Sciences Corporation",
        "news_type": "normal",
        "symbol": "EXAS",
        "title": "Exact Sciences revenue beats on strong Cologuard volumes "
    },
    {
        "content": "* Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S",
        "date": "07252017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences posts Q2 loss per share $0.27 "
    },
    {
        "content": "* Exact Sciences Corp -Exact Sciences Laboratories entered national ancillary provider participation agreement with Unitedhealthcare Insurance for cologuard",
        "date": "07052017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences laboratories enters national ancillary provider participation agreement with Unitedhealthcare Insurance "
    },
    {
        "content": "* Exact Sciences announces agreement to sell 7 000 000 common shares",
        "date": "06062017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences reports agreement to sell 7 mln common shares "
    },
    {
        "content": "* Exact sciences announces pricing of public offering of common stock",
        "date": "06072017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences says offering of 7 mln common shares priced at $35 per share "
    },
    {
        "content": "* Exact Sciences Corp - company anticipates revenue of $195 million-$205 million and completed Cologuard test volume of at least 470 000 tests during 2017 Source text for Eikon: Further company coverage:",
        "date": "04272017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences posts Q1 loss per share $0.32 "
    },
    {
        "content": "* Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics",
        "date": "04272017",
        "name": "Exact Sciences Corporation",
        "news_type": "normal",
        "symbol": "EXAS",
        "title": "BRIEF-Mdxhealth and Exact Sciences sign collaboration agreement "
    },
    {
        "content": "* Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S",
        "date": "02212017",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact sciences Q4 loss per share $0.34 "
    },
    {
        "content": "* Exact Sciences appoints Jeff Elliott chief financial officer  Source text for Eikon:  Further company coverage:",
        "date": "11082016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences appoints Jeff Elliott as CFO "
    },
    {
        "content": "* Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S",
        "date": "10262016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences Q3 loss per share $0.36 "
    },
    {
        "content": "* David shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing  Source text for Eikon:  Further company coverage:",
        "date": "08252016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-David Shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing "
    },
    {
        "content": "* D. E. Shaw & Co reports 5 pct passive stake in Exact Sciences as of July 22 - SEC filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "08012016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-D. E. Shaw & Co reports 5 pct passive stake in Exact Sciences as of July 22 - SEC Filing "
    },
    {
        "content": "* Files for potential mixed shelf - SEC filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07272016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences files for potential mixed shelf - SEC filing "
    },
    {
        "content": "* Selling 8.5 million shares of common stock through underwriters at a public offering price of $15.50 per share",
        "date": "07282016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences announces offering of 8.5 mln common stock "
    },
    {
        "content": "* Generated revenues of $21.2 million during Q2 ended June 30  2016  representing a 161-percent increase from $8.1 million in Q2 of 2015",
        "date": "07262016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences posts Q2 loss per share of $0.46 "
    },
    {
        "content": "* Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations",
        "date": "06152016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences'Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations "
    },
    {
        "content": "* Exact Sciences statement regarding pending USPSTF colorectal cancer screening guidelines",
        "date": "06152016",
        "name": "Exact Sciences Corporation",
        "news_type": "normal",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences statement regarding pending USPSTF colorectal cancer screening guidelines "
    },
    {
        "content": "* Expect total sales in second half of fiscal 2016 to be lower than they were in first half of fiscal 2016   Source text for Eikon:   Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05052016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Span-America Medical Systems Q2 earnings per share $0.28 "
    },
    {
        "content": "* Q1 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S",
        "date": "05032016",
        "name": "Exact Sciences Corporation",
        "news_type": "topStory",
        "symbol": "EXAS",
        "title": "BRIEF-Exact Sciences posts Q1 loss per share of $0.49 "
    }
]